Stimulation of immature lung macrophages with intranasal interferon gamma in a novel neonatal mouse model of respiratory syncytial virus infection

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Empey, Kerry M ^a   Orend, Jacob G ^a   Peebles, R Stokes ^d   Egaña, Loreto ^a   Norris, Karen A ^c   Oury, Tim D ^c   Kolls, Jay K ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 4; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL STIMULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION REGULATION; HEP 2 CELL; IMMUNOMODULATION; IN VITRO STUDY; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; LYMPHOCYTIC INFILTRATION; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION; WEIGHT GAIN;

ADMINISTRATION, INHALATION; ANIMALS; ANIMALS, NEWBORN; ANTIGEN-PRESENTING CELLS; ANTIVIRAL AGENTS; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON-GAMMA; LUNG; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED BALB C; MUCINS; PHENOTYPE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; T-LYMPHOCYTES; VIRAL LOAD;

MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84863707107     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040499     Document Type: Article

References (42)

1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, et al. (1999) Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282: 1440-1446.
2. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, et al. (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360: 588-598.
3. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, et al. (2010) Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 182: 1305-1314.
4. Welliver TP, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, et al. (2007) Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 195: 1126-1136.
5. Graham BS, Bunton LA, Wright PF, Karzon DT, (1991) Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 88: 1026-1033.
6. Heidema J, de Bree GJ, De Graaff PM, van Maren WW, Hoogerhout P, et al. (2004) Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J Gen Virol 85: 2365-2374.
7. Olson MR, Varga SM, (2007) CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol 179: 5415-5424.
8. Olson MR, Hartwig SM, Varga SM, (2008) The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J Immunol 181: 7958-7968.
9. Larranaga CL, Ampuero SL, Luchsinger VF, Carrion FA, Aguilar NV, et al. (2009) Impaired Immune Response in Severe Human Lower Tract Respiratory Infection by Respiratory Syncytial Virus. Pediatr Infect Dis J.
10. Harker JA, Lee DC, Yamaguchi Y, Wang B, Bukreyev A, et al. (2010) Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. J Virol 84: 5294-5302.
11. Lee YM, Miyahara N, Takeda K, Prpich J, Oh A, et al. (2008) IFN-gamma production during initial infection determines the outcome of reinfection with respiratory syncytial virus. Am J Respir Crit Care Med 177: 208-218.
12. Gordon S, (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
13. Gordon S, Martinez FO Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
14. Mosser DM, (2003) The many faces of macrophage activation. J Leukoc Biol 73: 209-212.
15. Mosser DM, Zhang X, (2008) Activation of murine macrophages. Curr Protoc Immunol Chapter 14: Unit 14 12.
16. Shirey KA, Pletneva LM, Puche AC, Keegan AD, Prince GA, et al. (2010) Control of RSV-induced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-beta-dependent. Mucosal Immunol 3: 291-300.
17. Graham BS, Perkins MD, Wright PF, Karzon DT, (1988) Primary respiratory syncytial virus infection in mice. J Med Virol 26: 153-162.
18. Empey KM, Hollifield M, Garvy BA, (2007) Exogenous heat-killed Escherichia coli improves alveolar macrophage activity and reduces Pneumocystis carinii lung burden in infant mice. Infect Immun 75: 3382-3393.
19. Qureshi MH, Garvy BA, (2001) Neonatal T cells in an adult lung environment are competent to resolve Pneumocystis carinii pneumonia. J Immunol 166: 5704-5711.
20. Hashimoto K, Graham BS, Geraci MW, FitzGerald GA, Egan K, et al. (2004) Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. J Virol 78: 10303-10309.
21. Woodside KH, Denas SM, Smith KL, Kim CS, Wanner A, (1983) Inhibition of pulmonary macrophage function by airway mucus. Journal of applied physiology 54: 94-98.
22. Gonzalez-Juarrero M, Shim TS, Kipnis A, Junqueira-Kipnis AP, Orme IM, (2003) Dynamics of macrophage cell populations during murine pulmonary tuberculosis. J Immunol 171: 3128-3135.
23. Graham BS, Johnson TR, Peebles RS, (2000) Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 48: 237-247.
24. You D, Becnel D, Wang K, Ripple M, Daly M, et al. (2006) Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults. Respir Res 7: 107.
25. Stout RD, Suttles J, (2004) Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 76: 509-513.
26. Stout RD, Suttles J, (2005) Immunosenescence and macrophage functional plasticity: dysregulation of macrophage function by age-associated microenvironmental changes. Immunol Rev 205: 60-71.
27. Edwards JP, Zhang X, Frauwirth KA, Mosser DM, (2006) Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 80: 1298-1307.
28. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO, (2003) Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 168: 633-639.
29. Becker Y, (2006) Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy-a review. Virus Genes 33: 235-252.
30. Lukacs NW, Moore ML, Rudd BD, Berlin AA, Collins RD, et al. (2006) Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am J Pathol 169: 977-986.
31. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS, (2007) The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20: 108-119.
32. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, et al. (2009) A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 83: 4185-4194.
33. Lanson NA Jr, Friedlander PL, Schwarzenberger P, Kolls JK, Wang G, (2003) Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res 63: 7936-7941.
34. Kaiko GE, Phipps S, Angkasekwinai P, Dong C, Foster PS, (2010) NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25. J Immunol 185: 4681-4690.
35. Benoit A, Huang Y, Proctor J, Rowden G, Anderson R, (2006) Effects of alveolar macrophage depletion on liposomal vaccine protection against respiratory syncytial virus (RSV). Clin Exp Immunol 145: 147-154.
36. Reed JL, Brewah YA, Delaney T, Welliver T, Burwell T, et al. (2008) Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis 198: 1783-1793.
37. Mokoena T, Gordon S, (1985) Human macrophage activation. Modulation of mannosyl, fucosyl receptor activity in vitro by lymphokines, gamma and alpha interferons, and dexamethasone. J Clin Invest 75: 624-631.
38. Cirino NM, Panuska JR, Villani A, Taraf H, Rebert NA, et al. (1993) Restricted replication of respiratory syncytial virus in human alveolar macrophages. J Gen Virol 74 (Pt 8): 1527-1537.
39. Midulla F, Huang YT, Gilbert IA, Cirino NM, McFadden ER Jr, et al. (1989) Respiratory syncytial virus infection of human cord and adult blood monocytes and alveolar macrophages. Am Rev Respir Dis 140: 771-777.
40. Panuska JR, Cirino NM, Midulla F, Despot JE, McFadden ER Jr, et al. (1990) Productive infection of isolated human alveolar macrophages by respiratory syncytial virus. J Clin Invest 86: 113-119.
41. Panuska JR, Hertz MI, Taraf H, Villani A, Cirino NM, (1992) Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients. Am Rev Respir Dis 145: 934-939.
42. Panuska JR, Merolla R, Rebert NA, Hoffmann SP, Tsivitse P, et al. (1995) Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages. Suppression of early cytokine production and implications for incomplete immunity. J Clin Invest 96: 2445-2453.